Clinical Trials in France / NCT07255157
Recruiting
Not applicable
Peripheral Helper T-cells in Common Variable ImmunoDeficiency
NCT07255157 · tracked via the Priya Life Science France tracker
Condition(s) studied
Common Variable Immunodeficiency
Investigational drug(s) / intervention(s)
blood sample
blood sample: 48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
Study summary
The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.
Eligibility
Inclusion Criteria:
* Male or female;
* Age ≥ 18 years;
* Standard criteria will be applied to diagnose CVID, specifically requiring: 1) low serum IgG level \<5 g/L, combined with low IgM- and/or IgA-isotype concentrations \<0.4 g/L or \<0.7 g/L, respectively; 2) poor antibody responses to immunization or infection; and 3) exclusion of other defined forms of secondary hypogammaglobulinemias. Patients meeting the definitional criteria for CVID will be included, regardless of the duration of the disease or the treatment received (gammaglobulins substitution or not);
* Being affiliated to health insurance;
* Willing to participate and to sign informed consent.
Exclusion Criteria:
* Patients on corticosteroids and/or immunosuppressants;
* Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;
* Patients with an active chronic infection;
* Pregnant or breastfeeding women;
* Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.
Primary outcome measure(s)
- Ability of Tph to promote differentiation and antibody production by memory B cells (B-T co-culture) — At baseline (Day 0)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU de Bordeaux - service de médecine interne | Pessac | France | Recruiting |
More University Hospital, Bordeaux trials in France
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07255157 on ClinicalTrials.gov ↗ ← All trials in France